1 |
van Beek DJ, Verschuur AVD, Brosens LAA, Valk GD, Pieterman CRC, Vriens MR. Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2023;32:343-71. [PMID: 36925190 DOI: 10.1016/j.soc.2022.10.010] [Reference Citation Analysis]
|
2 |
Fodil-Cherif S, Desailloud R, Brue T. Updates in neuroendocrine neoplasms: From mechanisms to the clinic. Ann Endocrinol (Paris) 2023:S0003-4266(23)00008-2. [PMID: 36690074 DOI: 10.1016/j.ando.2022.12.424] [Reference Citation Analysis]
|
3 |
Li Y, Luo Z, Wang X, Zhang S, Hei H, Qin J. Design of new drugs for medullary thyroid carcinoma. Front Oncol 2022;12:993725. [PMID: 36544713 DOI: 10.3389/fonc.2022.993725] [Reference Citation Analysis]
|
4 |
Hofland J, Brabander T, Verburg FA, Feelders RA, de Herder WW. Peptide Receptor Radionuclide Therapy. J Clin Endocrinol Metab 2022;107:3199-208. [PMID: 36198028 DOI: 10.1210/clinem/dgac574] [Reference Citation Analysis]
|
5 |
Pacak K, Taieb D, Jha A. Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient's Favor. J Clin Endocrinol Metab 2022;107:e3953-4. [PMID: 35536703 DOI: 10.1210/clinem/dgac298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|